Similar patterns were noted in landmark trials, such as the EMPA-REG OUTCOME and CANVAS, where patients with diabetes demonstrated higher event rates but also derived significant cardiovascular protection from SGLT-2 inhibitors [16]. Here, SLC5A2 is linked to diabetes mellitus.